Highlights

  • Ceretas (ASX: CTS) listed on the ASX on 23 July 2026 after raising approximately $8 million at 25 cents per share, giving it an indicative market capitalisation of around $17.8 million.
  • The company's technology is a non-invasive, portable therapeutic ultrasound platform licensed from the University of Queensland's Queensland Brain Institute, where it was developed over roughly a decade backed by about $20 million in research funding.
  • A Phase 1 safety trial in 12 mild-to-moderate Alzheimer's patients found the treatment safe and well tolerated, with results published in December 2025.
  • IPO proceeds are earmarked for the Phase 2 CERE-CALM trial, targeting around 66 Alzheimer's patients with behavioural and psychological symptoms of dementia, plus preclinical blood-brain barrier research.
  • The leadership team includes veterans of ASX-listed medtech, including former ResApp Health chief executive Dr Tony Keating and EMVision chairman John Keep.
  • As a pre-revenue, clinical-stage micro-cap, Ceretas carries substantial clinical, regulatory, reimbursement and funding risk, and remains years away from any potential commercialisation.

Few sectors carry more emotional weight, or more commercial promise, than the search for a workable treatment for Alzheimer's disease. So when Ceretas (ASX:CTS) rang the bell on the Australian Securities Exchange on 23 July 2026, having raised roughly $8 million in its initial public offering, it captured the attention of retail investors hunting for the next Australian medtech story. Spun out of the University of Queensland's Queensland Brain Institute, Ceretas is developing a non-invasive, portable ultrasound platform designed to treat neurodegenerative disease. Its shares traded above the 25-cent offer price on debut, a sign of the demand that co-founder Ryan Laws described in press interviews as a flood of interest. Yet a warm reception on day one tells investors little about the years of clinical, regulatory and reimbursement hurdles ahead. This article examines what Ceretas actually has, and what it must still prove.

A high-demand debut for a dementia hopeful

Ceretas Limited joined the ASX under the ticker CTS on 23 July 2026, completing an IPO that raised approximately $8 million through the issue of about 32 million fully paid ordinary shares at 25 cents each. That priced the newly listed company at an indicative market capitalisation of roughly $17.8 million.

The float drew unusually strong interest for a micro-cap biotech.25 ceche company completed its raise without a formal investor roadshow, and co-founder Ryan Laws was quoted describing the level of inbound interest as a good problem to have. Existing backers, including the Clem Jones Group, were reported to have increased their positions ahead of the float.

On its first day of trading the stock changed hands above the 25-cent offer price. A positive aftermarket is encouraging sentiment, but it is worth stating plainly: opening-day strength in a speculative, pre-revenue medtech is not a reliable guide to longer-term value. The real test lies in the clinic.

From the Queensland Brain Institute to the ASX

Ceretas is a commercialisation vehicle for research conducted at the University of Queensland's Queensland Brain Institute (QBI), where the therapeutic ultrasound platform was developed over roughly a decade. The company holds rights to the technology through UQ's commercialisation arm, UniQuest.

The founding science is associated with Professor Jurgen Gotz, director of the Clem Jones Centre for Ageing Dementia Research, alongside collaborators including neuroscientist Dr Gerhard Leinenga and cognitive neurologist Professor Peter Nestor. The company reports that the underlying research programme has been supported by approximately $20 million in funding over its lifetime, including a $5 million Queensland Government commitment announced in 2023.

The technology itself is a non-invasive, portable and comparatively low-cost ultrasound device. Ceretas describes it as working through several mechanisms: neuromodulation, in which focused ultrasound modulates neuronal activity without heating or damaging tissue; and the temporary, targeted opening of the blood-brain barrier, which the company says can assist clearance of the amyloid plaques and tau tangles associated with Alzheimer's and, potentially, help therapeutics reach the brain.

The management team is stacked with ASX medtech experience. Chief executive Dr Rachel de las Heras spent years overseeing the UQ-QBI ultrasound programme. Executive director Dr Tony Keating previously led ResApp Health, later acquired by Pfizer. Chairman John Keep also chairs ASX-listed EMVision Medical Devices, while co-founders Ryan Laws and Sam Wetzler bring corporate finance and investment backgrounds.

Why a non-invasive approach matters

The appeal of the Ceretas approach lies in the biology of the brain. The company cites the widely quoted figure that the overwhelming majority of neurological drugs cannot cross the blood-brain barrier, the protective membrane that keeps most large molecules out of brain tissue. That barrier is a central reason so many promising dementia therapies have failed to translate into meaningful clinical benefit.

Ultrasound offers a fundamentally different route. If the technology performs as hoped, it could either stimulate neural circuits directly or transiently open the barrier to allow clearance of toxic proteins, without surgery, implants or systemic drugs. A portable, lower-cost device would also, in principle, be easier to deploy across clinics than the large fixed-site systems used in some competing focused-ultrasound approaches.

That is the thesis. It is important to distinguish the promise from the proof. The mechanism is scientifically plausible and supported by preclinical work in animal models, but its clinical value in humans is precisely what the company's trial programme must now establish.

The clinical evidence so far

The most concrete evidence to date is a Phase 1 study. Ceretas reports that a first-in-human safety trial enrolled 12 patients with mild-to-moderate Alzheimer's disease, and that the treatment proved safe and well tolerated, with results published in December 2025. Early-stage safety data of this kind is a necessary foundation, but a 12-patient trial is not designed to prove efficacy.

The next step, and the primary use of IPO proceeds, is the Phase 2 CERE-CALM trial. According to the listing materials, this study targets around 66 Alzheimer's patients (with a minimum of 60) who experience behavioural and psychological symptoms of dementia (BPSD). The design involves six treatment sessions over 12 weeks, with participants randomised on a two-to-one basis between active treatment and a sham control.

A sham-controlled, randomised design is the right methodology for generating credible efficacy data, and the focus on BPSD, agitation, aggression and related symptoms, targets an area of genuine unmet need where treatment options are limited. Investors should note, however, that a study of this size is still relatively small, and positive Phase 2 signals in neuroscience have historically failed to replicate in larger, pivotal trials more often than in most therapeutic areas.

Ceretas has not, on the sources reviewed, detailed a definitive regulatory pathway with the TGA, FDA or EMA, nor a specific timeline to registration. As with any device-based therapy, the eventual path to market, and to reimbursement, will depend heavily on the strength and consistency of the clinical data it generates.

A vast but difficult addressable market

The market opportunity in dementia is enormous by any measure. The company points to global figures suggesting a new dementia diagnosis somewhere in the world roughly every three seconds, with Alzheimer's accounting for the majority of cases, and forecasts that the total dementia population will continue climbing over the coming decade.

That scale is precisely what makes the sector attractive to investors and, at the same time, so treacherous. The same large, ageing patient population that represents the commercial upside has also absorbed decades of failed drug candidates and billions in write-offs across the global pharmaceutical industry.

For Ceretas, the addressable market is best understood as a long-term aspiration rather than a near-term revenue line. Even in a favourable scenario, capturing a share of it would require successful late-stage trials, regulatory clearance, manufacturing scale-up and reimbursement arrangements, none of which are yet in hand.

Potential catalysts and material risks

The clearest potential catalysts are clinical. Enrolment progress and, ultimately, headline results from the CERE-CALM Phase 2 trial would be the most significant value inflection points. Positive preclinical data on blood-brain barrier opening, any move toward regulatory engagement, and potential partnering or licensing interest from larger players could also shift sentiment.

The risks are equally clear and, for a company at this stage, arguably dominant. Clinical risk is paramount: the treatment may simply fail to show a statistically meaningful benefit in a controlled setting. Regulatory risk follows, as novel device-based neurological therapies face demanding approval requirements. Reimbursement risk is real too, because even an approved therapy must persuade payers of its cost-effectiveness.

Then there is funding risk. As a pre-revenue clinical-stage micro-cap, Ceretas will consume cash as it runs its trials, and the reviewed sources did not disclose a specific cash runway or burn rate. Should the Phase 2 programme extend or expand, the company may need to return to the market to raise further capital, which could dilute existing shareholders. Investors should treat this as a speculative, binary-outcome holding rather than a stable operating business.

A balanced outlook for CTS

What Ceretas offers is a credible scientific idea, an experienced board and management team, a licence to a decade of publicly funded research, and a clearly defined next clinical milestone, all wrapped in a modest market capitalisation. That combination explains the enthusiastic reception at listing.

What it does not yet offer is proof that the technology changes outcomes for patients in a rigorous, controlled trial, a defined regulatory route to market, or revenue. Those are substantial gaps, and the history of dementia research counsels caution about assuming they will be closed.

For sophisticated retail investors, the sensible framing is neither hype nor dismissal. Ceretas sits firmly in the high-risk, high-uncertainty end of the market, where the outcome of a single trial can make or unmake the investment case. This article does not constitute financial advice, and readers should weigh the company's early stage, funding needs and clinical uncertainty against their own risk tolerance.

Conclusion

Ceretas (ASX: CTS) has arrived on the ASX with a compelling narrative: a home-grown, non-invasive ultrasound technology aimed at one of medicine's hardest problems, backed by researchers and executives who have built and sold medtech businesses before. The strong debut and the roughly $8 million war chest give it the means to run its pivotal next study.

But the company's value ultimately rests on data it has not yet produced. If the CERE-CALM Phase 2 trial delivers a clear, controlled signal of benefit, Ceretas could become one of the more talked-about names in Australian medtech. If it does not, the risks outlined here will come to the fore. For now, Ceretas (ASX: CTS) is best watched as a genuinely interesting, and genuinely speculative, clinical-stage story whose defining chapters are still to be written.